Ministers agree on international action to address antimicrobial resistance in animals and to safeguard medicines for humans and animals alike

Milestones :: Perspectives

Ministers agree on international action to address antimicrobial resistance in animals and to safeguard medicines for humans and animals alike

Marrakesh, 31 October 2018 –  The World Organisation for Animal Health (OIE) hosted this week global leaders in animal health from the private and public sectors and civil society to discuss new ideas and solutions to the global rise of antimicrobial resistance (AMR). The three-day event was placed under the high patronage of his majesty Mohammed VI, King of Morocco. Entitled the 2nd Global Conference on Antimicrobial Resistance and Prudent Use of Antimicrobial Agents in Animals, it focussed on the role played by animal health in what is one of the 21st century’s starkest global health challenges.

Prevention of AMR in farming is critical to human health, as well as to food safety, food security, animal health and animal welfare. Antimicrobials are used around the world to control and treat infections in animals and humans, but their overuse and misuse puts their efficacy at risk. Unprecedented movements of people, animals, goods and food worldwide, enable resistant pathogens to populate the planet with ease.

The conference was attended by more than 500 participants, including representatives of OIE’s 182 Member Countries, of international partners (such as FAO, WHO, World Bank, and the United Nations Interagency Coordination Group on AMR), as well as representatives from the meat, dairy, poultry, egg, aquaculture and pharmaceutical industries, civil society and academia.

A prominent theme of the discussions was the need for cross-sector, national level coordination through national action plans to prevent the development and spread of antimicrobial resistance. Conference speakers included Ministers, Deputy Ministers and State Secretaries from countries across the world, including Morocco, Germany, Senegal, Thailand, Japan, Norway, Botswana, Serbia, and Uzbekistan.

“It is only by promoting the responsible and prudent use of antimicrobials that their efficacy can be safeguarded, ensuring that essential medicines that protect both human and animal health can continue to be used.” said Dr Monique Eloit, Director General of OIE. “We have made important progress in this mission today. International Standards on prudent use already exist. We now need to put them into practice at national level to tackle AMR. For this, international collaboration is essential. By working together, countries can discuss challenges, share best practice and make global improvements.”

13: Situation report on the Ebola outbreak in North Kivu  :: DONs Ebola virus disease – Democratic Republic of the Congo  

Milestones :: Perspectives

Ebola – Democratic Republic of the Congo

13: Situation report on the Ebola outbreak in North Kivu 
30 October 2018
The Ebola virus disease (EVD) outbreak in North Kivu and Ituri provinces, Democratic Republic of the Congo continues to be closely monitored by the Ministry of Health (MoH), WHO and partners.  Of concern is the increased incidence of confirmed cases reported in the past four weeks, most notably in the city of Beni and communities around Butembo. Security remains the biggest challenge faced by the response teams in Beni and Butembo, undermining the response activities. Continued security incidents severely impact both civilians and frontline workers, forcing suspension of EVD response activities and increasing the risk that the virus will continue to spread. Moreover, with heightened transmission of the virus in outbreak affected areas, the risk of exportation of cases to neighbouring provinces and countries is increased. Neighbouring countries need to be ready in case the outbreak spreads beyond the Democratic Republic of the Congo….

DONs Ebola virus disease – Democratic Republic of the Congo
1 November 2018
[Excerpts]
Vaccination: As of 31 October, 154 vaccination rings have been defined, in addition to 37 rings of health and frontline worker. To date, 25 298 eligible and consented people have been vaccinated, including 8916 health and frontline workers and 6578 children. Overall, vaccination teams have reached an additional 3345 eligible and consenting people in the past week.
Partners
To support the MoH, WHO is working intensively with a wide range of multisectoral and multidisciplinary regional and global partners and stakeholders for EVD response, research and urgent preparedness, including in neighbouring countries. Among the partners are a number of UN agencies and international organizations including: European Civil Protection and Humanitarian Aid Operation (ECHO); International Organization for Migration (IOM); UK Public Health Rapid Support Team; United Nations Children’s Fund (UNICEF); UN High Commission on Refugees (UNHCR); World Bank and regional development banks; World Food Programme (WFP) and UN Humanitarian Air Service (UNHAS); UN mission and UN Department of Safety and Security (UNDSS); Inter-Agency Standing Commission; United Nations Office for the Coordination of Humanitarian Affairs (OCHA); and the United Nations Population Fund (UNFPA); Africa Centres for Disease Control; US CDC; UK Department for International Development (DFID); United States Agency for International Development (USAID); Adeco Federación (ADECO); Association des femmes pour la nutrition à assisse communautaire (AFNAC); Alliance for International Medical Action (ALIMA); CARITAS DRC; CARE International; Centre de promotion socio-sanitaire (CEPROSSAN); Cooperazione Internationale (COOPE); Catholic Organization for Relief and Development Aid (CORDAID/PAP-DRC); International Medical Corps; International Rescue Committee (IRC); Intersos – Organizzatione Umanitaria par l’Emergenza (INTERSOS); MEDAIR; Médecins Sans Frontières (MSF); Oxfam International; Red Cross of the Democratic Republic of Congo, with the support of the International Federation of Red Cross and Red Crescent Societies (IFRC) and International Committee of the Red Cross (ICRC); Samaritan’s Purse; Save the Children (SCI); Global Outbreak Alert and Response Network (GOARN), Emerging and Dangerous Pathogens Laboratory Network (EDPLN), Emerging Disease Clinical Assessment and Response Network (EDCARN), technical networks and operational partners, and the Emergency Medical Team Initiative (EMT). GOARN partners continue to support the response through deployment for response and readiness activities in non-affected provinces and in neighbouring countries and to different levels of WHO.

Adopting Resolution 2439 (2018), Security Council Condemns Attacks by Armed Groups in Democratic Republic of Congo Jeopardizing Response to Ebola Outbreak

Milestones :: Perspectives

Adopting Resolution 2439 (2018), Security Council Condemns Attacks by Armed Groups in Democratic Republic of Congo Jeopardizing Response to Ebola Outbreak
30 October 2018
SC/13559
The Security Council today adopted a resolution condemning attacks by armed groups in the Democratic Republic of the Congo and their role in exacerbating the country’s ongoing Ebola outbreak, while demanding full, safe, immediate and unhindered access for the humanitarian and medical personnel working to save lives and prevent the virus from spreading across the region.

::::::

:: Uganda Finalizes Plans to Vaccinate Front-line Health Workers against Ebola  03 November 2018

:: Zambia heightens its capacity for preventing and responding to the threat of an outbreak of Ebola Virus Disease  02 November 2018

:: WHO enhances Ebola Rapid Response Readiness Capacities in South Sudan  01 November 2018

:: WHO and the Ministry of Health Train Members of the Armed Forces on Ebola Case Management [Uganda]  29 October 2018

 

Emergencies

Emergencies
 
 
POLIO
Public Health Emergency of International Concern (PHEIC)
Polio this week as of 30 October 2018 [GPEI]
:: World Polio Day activities garnered global attention. Partners, donors, and popular public figures around the world brought attention to the cause of polio and the efforts to eradicate polio. A quick overview of some of the World Polio Day highlights
:: The Every Last Child project series was launched by UNICEF, which covers over 30 wide-ranging profiles of governments, front-line workers, and the stakeholders involved in the collective polio eradication efforts across Nigeria, Afghanistan, and Pakistan.
:: Featured on polioeradication.org: Coffee with Polio Experts – Dr Arlene King, Chair of the RCC for the Americas, and GCC Containment Working Group talks to WHO about the importance of safe and secure containment of polioviruses, in places where needed, and the accompanying risk and responsibility that come with retaining the pathogen.
 
 
Afghanistan – Three new cases of wild poliovirus (WPV1) and four WPV1 positive environmental samples.

Democratic Republic of Congo – one new case of circulating vaccine-derived poliovirus type 2 (cVDPV2).

Pakistan – No new case of wild poliovirus (WPV1) and seven WPV1 positive environmental samples

Nigeria – two new cases of circulating vaccine-derived poliovirus type 2 (cVDPV2).

Somalia – four new cVDPV2 positive environmental samples. See country sections below for more details.

::::::
::::::

Editor’s Note:

WHO has posted a refreshed emergencies page which presents an updated listing of Grade 3,2,1 emergencies as below.

WHO Grade 3 Emergencies  [to 3 Nov 2018 ]
Democratic Republic of the Congo
:: 13: Situation report on the Ebola outbreak in North Kivu  30 October 2018
:: DONs Ebola virus disease – Democratic Republic of the Congo  1 November 2018
[See Milestones above for more detail]
 
 
Bangladesh – Rohingya crisis
:: Weekly Situation Report 48 – 25 October 2018
[Excerpt]
…WHO immunization team is planning to start passive surveillance activity of Acute Flaccid Paralysis (AFP), Vaccine Preventable diseases m(VPDs), Congenital rubella syndrome (CRS) and Adverse Event Following Immunization (AEFIs) for early notification and in compliance with the

Ministry of Health (MoH) surveillance program….

 
Nigeria – No new announcements identified
Somalia – No new announcements identified
South Sudan – No new announcements identified
Syrian Arab Republic – No new announcements identified
Yemen – No new announcements identified

::::::

 
WHO Grade 2 Emergencies  [to 3 Nov 2018 ]
Myanmar
:: Weekly Situation Report 48 – 25 October 2018 [see above]

Brazil (in Portugese) – No new announcements identified
Cameroon  – No new announcements identified
Central African Republic  – No new announcements identified
Ethiopia – No new announcements identified
Hurricane Irma and Maria in the Caribbean – No new announcements identified
Iraq – No new announcements identified
occupied Palestinian territory – No new announcements identified
Libya – No new announcements identified
MERS-CoV – No new announcements identified
Niger – No new announcements identified
Sao Tome and Principe Necrotizing Cellulitis (2017) – No new announcements identified
Sudan – No new announcements identified
Ukraine – No new announcements identified
Zimbabwe – No new announcements identified

Outbreaks and Emergencies Bulletin, Week 43: 20 – 26 October 2018
The WHO Health Emergencies Programme is currently monitoring 55 events in the region. This week’s edition covers key ongoing events, including:
:: Ebola virus disease outbreak in the Democratic Republic of the Congo
:: Cholera in Cameroon
:: Dengue in Senegal
:: Hepatitis E in Central African Republic.

::::::

 

WHO Grade 1 Emergencies  [to 3 Nov 2018 ]
Afghanistan
Angola (in Portuguese)
Chad
Ethiopia
Kenya

Lao People’s Democratic Republic
Mali
Papua New Guinea
Peru
Tanzania
Tropical Cyclone Gira
Zambia
 
::::::
 
UN OCHA – L3 Emergencies
The UN and its humanitarian partners are currently responding to three ‘L3’ emergencies. This is the global humanitarian system’s classification for the response to the most severe, large-scale humanitarian crises. 
Syrian Arab Republic   No new announcements identified.
YemenNo new announcements identified.

::::::

UN OCHA – Corporate Emergencies
When the USG/ERC declares a Corporate Emergency Response, all OCHA offices, branches and sections provide their full support to response activities both at HQ and in the field.

Ethiopia 
:: Ethiopia Humanitarian Bulletin Issue 66 | 15-28 October 2018
 
Somalia  No new announcements identified.
 
::::::
 
“Other Emergencies”
Indonesia: Central Sulawesi Earthquake
:: Central Sulawesi Earthquake & Tsunami: Humanitarian Country Team Situation Report #6 (as of 30 October 2018)

::::::
::::::

Editor’s Note:

We will cluster these recent emergencies as below and continue to monitor the WHO webpages for updates and key developments.

EBOLA/EVD  [to 3 Nov 2018 ]
http://www.who.int/ebola/en/
[See Milestones above for more detail]

MERS-CoV [to 3 Nov 2018 ]
http://who.int/emergencies/mers-cov/en/
No new announcements identified.
 
Yellow Fever  [to 3 Nov 2018 ]
http://www.who.int/csr/disease/yellowfev/en/
No new announcements identified.
 
Zika virus  [to 3 Nov 2018 ]
http://www.who.int/csr/disease/zika/en/
No new announcements identified.

::::::
::::::
 
WHO & Regional Offices [to 3 Nov 2018 ]
News Release
29 October 2018
More than 90% of the world’s children breathe toxic air every day

::::::
 
Weekly Epidemiological Record, 2 November 2018, vol. 93, 44 (pp. 589–604)
:: Global programme to eliminate lymphatic filariasis: progress report, 2017
:: Monthly report on dracunculiasis cases, January-September 2018

::::::
 
WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region AFRO
Selected Featured News
:: Uganda Finalizes Plans to Vaccinate Front-line Health Workers against Ebola  03 November 2018
:: Zambia heightens its capacity for preventing and responding to the threat of an outbreak of Ebola Virus Disease
02 November 2018
:: WHO enhances Ebola Rapid Response Readiness Capacities in South Sudan  01 November 2018
:: WHO and the Ministry of Health Train Members of the Armed Forces on Ebola Case Management [Uganda]  29 October 2018

WHO Region of the Americas PAHO
:: ‘Health is a right of the people and a responsibility of government,’ says PAHO Director (10/29/2018)

 
WHO South-East Asia Region SEARO
– No new announcement identified
 
WHO European Region EURO
:: Simulated poliovirus containment breach helps countries increase biorisk safety and security 01-11-2018
:: Revitalizing primary health care for the 21st century 01-11-2018

WHO Eastern Mediterranean Region EMRO
– No new announcement identified

WHO Western Pacific Region
:: 31 October 2018 – Singapore wipes out measles; Australia, Brunei Darussalam and Macao SAR (China) eliminate rubella
:: 30 October 2018  – Joint News Release  Regional Conference towards the Implementation of INSPIRE: Seven Strategies for Ending Violence against Children

CDC/ACIP [to 3 Nov 2018 ]

CDC/ACIP [to 3 Nov 2018 ]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html

MMWR News Synopsis for November 2, 2018
Update: Recommendations of the Advisory Committee on Immunization Practices for Use of Hepatitis A Vaccine for Postexposure Prophylaxis and for Preexposure Prophylaxis for International Travel
The Advisory Committee on Immunization Practices updated its recommendations on the use of hepatitis A (HepA) vaccine for postexposure prophylaxis and the use of HepA vaccine in infants prior to international travel. Postexposure prophylaxis (PEP) with HepA vaccine or immune globulin (IG) prevents hepatitis A virus infection (HAV) if given within two weeks of exposure. In February 2018, the Advisory Committee on Immunization Practices (ACIP) approved an update of recommendations for use of HepA vaccine for PEP in healthy persons 12 months and older. In addition to HepA vaccine, IG may be administered to persons over 40 years of age, depending on the provider’s risk assessment. HepA vaccine efficacy and safety in infants and the benefits of protection against HAV before international travel were also reviewed. ACIP recommended that HepA vaccine be administered to infants aged 6–11 months traveling outside the United States when protection against HAV is recommended. The updated recommendations specify new guidance for administering PEP for people over 40, and infants for international travel.

::::::

Announcements

Announcements
 
BMGF – Gates Foundation  [to 3 Nov 2018 ]
http://www.gatesfoundation.org/Media-Center/Press-Releases
No new digest content identified.
 
 
Bill & Melinda Gates Medical Research Institute    [to 3 Nov 2018 ]
https://www.gatesmri.org/
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.
 
 
CARB-X   [to 3 Nov 2018 ]
https://carb-x.org/
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
No new digest content identified.
 
 
CEPI – Coalition for Epidemic Preparedness Innovations  [to 3 Nov 2018 ]
http://cepi.net/
No new digest content identified.
 
 
EDCTP    [to 3 Nov 2018 ]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
1 November 2018
EDCTP and Wellcome Trust organise session at ASTMH 2018
EDCTP and the Wellcome Trust organised a session on controlled Human Infection Studies in low- and middle-income countries as a contribution to the ASTMH 2018 programme. The symposium (session 169) takes place on 1 November from 08:00-09:45.
 
 
Emory Vaccine Center    [to 3 Nov 2018 ]
http://www.vaccines.emory.edu/
No new digest content identified.
 
 
European Medicines Agency  [to 3 Nov 2018 ]
http://www.ema.europa.eu/ema/
News and press releases
No new digest content identified.
 
 
European Vaccine Initiative  [to 3 Nov 2018 ]
http://www.euvaccine.eu/news-events
No new digest content identified.
 
 
FDA [to 3 Nov 2018 ]
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm
November 01, 2018 –
Jeffrey Shuren, M.D., J.D., director of the FDA’s Center for Devices and Radiological Health and Janet Woodcock, M.D., director of the FDA’s Center for Drug Evaluation and Research on agency’s warning to consumers about genetic tests that claim to predict patients’ responses to specific medications
 
 
Fondation Merieux  [to 3 Nov 2018 ]
http://www.fondation-merieux.org/
Mérieux Foundation co-organized event
Case Management working group / Global Task Force on Cholera Control (GTFCC)
November 5 – 6, 2018 – Les Pensieres Center for Global Health, Veyrier-du-Lac (France)
 
Mérieux Foundation co-organized event
Dengue pre-vaccination screening based on serostatus: rapid tests and implementation strategies
January 14 – 16, 2019 – Les Pensières Center for Global Helath, Veyrier du Lac (France)
 
 
Gavi [to 3 Nov 2018 ]
https://www.gavi.org/
31 October 2018
200,000 girls in Senegal to be protected this year against cervical cancer
… The vaccines, funded by Gavi, the Vaccine Alliance and the Government of Senegal, will reach close to 200,000 nine-year-old girls across the country this year and a further 900,000 girls aged 11-14 years next year. UNICEF, WHO and partners will work on implementation alongside the Senegal Ministry of Health and Social Welfare and the Ministry of National Education….
 
 
30 October 2018
Hundreds of thousands of children set to be protected against the leading cause of pneumonia in Haiti
Port-au-Prince, 30 October 2018 – The government of Haiti formally introduced yesterday pneumococcal conjugate vaccine (PCV) into its routine immunisation programme, which will protect hundreds of thousands of Haitian children against pneumococcal disease, the leading cause of pneumonia… With this introduction, as many as 270,000 Haitian children will routinely receive PCV every year – along with pentavalent and rotavirus vaccines which Haiti introduced with support from Gavi, the Vaccine Alliance in 2012 and 2014.
 
 
GHIT Fund   [to 3 Nov 2018 ]
https://www.ghitfund.org/newsroom/press
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that devastate the world’s poorest people. Other funders include six Japanese pharmaceutical
No new digest content identified.
 
 
Global Fund  [to 3 Nov 2018 ]
https://www.theglobalfund.org/en/news/
Voices
What’s new about the New Nets Project?
31 October 2018
The Global Fund and Unitaid are each investing US$33 million from 2018 to 2022 to introduce new insecticide-treated nets to fight malaria-carrying mosquitoes.
 
 
Hilleman Laboratories   [to 3 Nov 2018 ]
http://www.hillemanlabs.org/
No new digest content identified.
 
 
Human Vaccines Project   [to 3 Nov 2018 ]
http://www.humanvaccinesproject.org/media/press-releases/
Event
Towards a Universal Influenza Vaccine: Lessons from the Great Influenza Pandemic of 1918 to Now
November 15-16, 2018 I Nashville, TN
The Human Vaccines Project is hosting a scientific summit featuring prominent researchers and thought leaders to discuss cutting-edge influenza research. The 2-day meeting will bring together leading scientists, clinicians and public health specialists including: John Barry, James E. Crowe, Jr., Senator Bill Frist, and Laurie Garrett.  Find a full agenda at:
www.humanvaccinesproject.org/talks/universalinfluenzavaccinesummit

November 01, 2018
Human Vaccines Project Launches New Study to Decode Immune Responses to Influenza
 
 
IAVI  [to 3 Nov 2018 ]
https://www.iavi.org/newsroom
No new digest content identified.
 
 
IFFIm
http://www.iffim.org/library/news/press-releases/
No new digest content identified.
 
 
IVAC  [to 3 Nov 2018 ]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
October 2018
Commentary: Pneumonia, Diarrhea, and Measles force Bangladeshi households to make difficult financial decisions when illnesses arise
Few diseases have as much power to cause wide-ranging impact among the population as pneumonia, diarrhea, and measles. These three illnesses can cause long-term disability and can require a significant amount of care. In addition to the pain and the risk of death or disability, people experiencing these illnesses face economic consequences now rising like out-of-pocket expenditures.
 
 
IVI   [to 3 Nov 2018 ]
http://www.ivi.int/
01/11/2018
The GTFCC Marks a Year of Progress Toward Ending Cholera Worldwide
 [See Milestones above for more detail]
 
 
JEE Alliance  [to 3 Nov 2018 ]
https://www.jeealliance.org/
No new digest content identified.
 
 
MSF/Médecins Sans Frontières  [to 3 Nov 2018 ]
http://www.msf.org/
Central African Republic
More than 10,000 seek refuge in Batangafo hospital
2 Nov 2018
Refugees, IDPs and people on the move
“Leaving the country to seek asylum is often the only option for survival”
29 Oct 2018
 
 
NIH  [to 3 Nov 2018 ]
http://www.nih.gov/news-events/news-releases
No new digest content identified.
 
 
PATH  [to 3 Nov 2018 ]
https://www.path.org/media-center/
No new digest content identified.
 
 
Sabin Vaccine Institute  [to 3 Nov 2018 ]
http://www.sabin.org/updates/pressreleases
No new digest content identified.
 
 
UNAIDS [to 3 Nov 2018 ]
http://www.unaids.org/en
2 November 2018
Civil society cooperation network for the Americas and the Caribbean launched
2 November 2018
New data dashboard launched in the Asia and the Pacific region
1 November 2018
New commitment to primary health care
31 October 2018
HIVR4P 2018 highlights new possibilities for HIV prevention
30 October 2018
Training the next generation of Russian doctors on HIV-related stigma and discrimination
29 October 2018
Global HIV prevention targets at risk
 
 
UNICEF  [to 3 Nov 2018 ]
https://www.unicef.org/media/press-releases
Selected Press Releases/Reports/Statements
Press release
In Mexico, children traveling with migrant caravan still in need of protection and support – UNICEF
01/11/2018
Press release
More than 80,000 children returned from Angola to DR Congo in urgent need of humanitarian assistance – UNICEF
30/10/2018
Press release
Global Task Force on Cholera Control marks a year of progress toward ending cholera worldwide
01/11/2018

[See Milestones above for more detail]
 
 
Vaccine Confidence Project  [to 3 Nov 2018 ]
http://www.vaccineconfidence.org/
No new digest content identified.
 
 
Vaccine Education Center – Children’s Hospital of Philadelphia  [to 3 Nov 2018 ]
http://www.chop.edu/centers-programs/vaccine-education-center
No new digest content identified.
 
 
Wellcome Trust  [to 3 Nov 2018 ]
https://wellcome.ac.uk/news
31 October 2018
How to make sense of the brain’s billions of neurons
A unique global collaboration has produced a new technology that will transform the way we study the brain. Neuropixels allow simultaneous recordings from many hundreds of neurons over multiple brain regions.
 
 
The Wistar Institute   [to 3 Nov 2018 ]
https://www.wistar.org/news/press-releases
No new digest content identified.
 
 
World Organisation for Animal Health (OIE)   [to 3 Nov 2018 ]
http://www.oie.int/en/for-the-media/press-releases/2018/
31/10/18
Ministers agree on international action to address antimicrobial resistance in animals and to safeguard medicines for humans and animals alike

[See Milestones above for more detail]

::::::
 
BIO    [to 3 Nov 2018 ]
https://www.bio.org/insights/press-release
No new digest content identified.
 
 
DCVMN – Developing Country Vaccine Manufacturers Network  [to 3 Nov 2018 ]
http://www.dcvmn.org/
29 October 2018 to 31 October 2018
19th DCVMN Annual General Meeting
Kunming / China
 
 
IFPMA   [to 3 Nov 2018 ]
http://www.ifpma.org/resources/news-releases/
Published on: 29 October 2018
The R&D biopharmaceutical industry supports the Astana Declaration and renewed political commitment towards the importance of primary health care
26 October 2018, Astana – The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the body accredited by the United Nations (UN) to represent the R&D biopharmaceutical industry attended Astana at the Global Conference on Primary Health Care on 25-26 October, co-hosted by the Government of Kazakhstan, WHO and UNICEF. R&D biopharmaceutical industry announced its support for the Astana Declaration and welcomed the renewed political commitment towards the importance of primary health care.  The industry body used the occasion to present a number of initiatives that are being pioneered to improve access to treatments and systems that ensure access at the primary care level.

Thomas Cueni, Director General, IFPMA delivered the following message at the Global Conference on Primary Health Care: “The research-based biopharmaceutical industry acknowledges that it needs to do more and do better to bring the fruits of its innovation to all, regardless of economic circumstances. Our industry is much more than a supplier of medicines and vaccines and is pioneering ways to overcome the multiple barriers to access to quality healthcare. Developing more collaborations at the primary health care level will enable healthcare companies to deliver products and services more efficiently and can accelerate progress towards reaching Universal Health Coverage”…
 
 
PhRMA    [to 3 Nov 2018 ]
http://www.phrma.org/press-room
No new digest content identified.

Reports/Research/Analysis/Commentary/Conferences/Meetings/Book Watch/Tenders

Reports/Research/Analysis/Commentary/Conferences/Meetings/Book Watch/Tenders

Vaccines and Global Health: The Week in Review has expanded its coverage of new reports, books, research and analysis published independent of the journal channel covered in Journal Watch below. Our interests span immunization and vaccines, as well as global public health, health governance, and associated themes. If you would like to suggest content to be included in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

 

No new digest content identified.

Journal Watch

Journal Watch

   Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

 

 

Influenza vaccine coverage and predictive factors associated with influenza vaccine uptake among pediatric patients

American Journal of Infection Control
November 2018 Volume 46, Issue 11, p1201-1318
http://www.ajicjournal.org/current

Major Articles
Influenza vaccine coverage and predictive factors associated with influenza vaccine uptake among pediatric patients
Celeste L.Y. Ewig, Ka Ming Tang, Ting Fan Leung, Joyce H.S. You
p1278–1283
Published online: May 23, 2018
 

Increasing transparency and accountability in national pharmaceutical systems

Bulletin of the World Health Organization
Volume 96, Number 11, November 2018, 729-796
http://www.who.int/bulletin/volumes/96/11/en/

POLICY & PRACTICE
Increasing transparency and accountability in national pharmaceutical systems
– Anne Paschke, Deirdre Dimancesco, Taryn Vian, Jillian C Kohler & Gilles Forte
http://dx.doi.org/10.2471/BLT.17.206516
Abstract
Access to safe, effective, good-quality medicines can be compromised by poor pharmaceutical system governance. This system is particularly vulnerable to inefficiencies and to losses from corruption, because it involves a complex mix of actors with diverse responsibilities. A high level of transparency and accountability is critical for minimizing opportunities for fraud and leakage. In the past decade, the Good Governance for Medicines programme and the Medicines Transparency Alliance focused on improving accountability in the pharmaceutical system and on reducing its vulnerability to corruption by increasing transparency and encouraging participation by a range of stakeholders. Experience with these two programmes revealed that stakeholders interpreted transparency and accountability in a range of different ways. Moreover, programme implementation and progress assessments were complicated by a lack of clarity about what information should be disclosed by governments and about how greater transparency can strengthen accountability for access to medicines. This article provides a conceptual understanding of how transparency can facilitate accountability for better access to medicines. We identified three categories of information as prerequisites for accountability: (i) standards and commitments; (ii) decisions and results; and (iii) consequences and responsive actions. Examples are provided for each. Conceptual clarity and practical examples of the information needed to ensure accountability can help policy-makers identify the actions required to increase transparency and accountability in their pharmaceutical systems. We also discuss factors that can hinder or facilitate the use of information to hold to account those responsible for improving access to medicines.

 

Best practices in scaling digital health in low and middle income countries

Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 3 Nov 2018 ]

Review
Best practices in scaling digital health in low and middle income countries
Healthcare challenges in low and middle income countries (LMICs) have been the focus of many digital initiatives that have aimed to improve both access to healthcare and the quality of healthcare delivery.
Authors: Alain B. Labrique, Christina Wadhwani, Koku Awoonor Williams, Peter Lamptey, Cees Hesp, Rowena Luk and Ann Aerts
Citation: Globalization and Health 2018 14:103
Published on: 3 November 2018

Expanding global access to essential medicines: investment priorities for sustainably strengthening medical product regulatory systems

Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 3 Nov 2018 ]

Review
Expanding global access to essential medicines: investment priorities for sustainably strengthening medical product regulatory systems
Access to quality-assured medical products improves health and save lives. However, one third of the world’s population lacks timely access to quality-assured medicines while estimates indicate that at least 1…
Authors: Lukas Roth, Daniel Bempong, Joseph B. Babigumira, Shabir Banoo, Emer Cooke, David Jeffreys, Lombe Kasonde, Hubert G. M. Leufkens, John C. W. Lim, Murray Lumpkin, Gugu Mahlangu, Rosanna W. Peeling, Helen Rees, Margareth Ndomondo-Sigonda, Andy Stergachis, Mike Ward…
Citation: Globalization and Health 2018 14:102
Published on: 1 November 2018

Rohingya refugees in Bangladesh: the humanitarian response

Humanitarian Exchange Magazine
Number 73,  October 2018
https://odihpn.org/magazine/mental-health-and-psychosocial-support-in-humanitarian-crises/

Rohingya refugees in Bangladesh: the humanitarian response

More than 700,000 Rohingya refugees have arrived in Bangladesh since 25 August 2017 fleeing violence and persecution in Rakhine State, Myanmar. Over a million are sheltering in overcrowded camps without adequate assistance or protection. Stateless in Myanmar and denied refugee status in Bangladesh, the Rohingya have few rights or freedoms. Monsoons and cyclones are causing landslides, destroying shelters and infrastructure and disrupting services.

This edition of Humanitarian Exchange focuses on the humanitarian response to the Rohingya crisis. In the lead article, Mark Bowden outlines the historical, local and national political context in Bangladesh, and its operational implications. Amal de Chickera highlights the links between statelessness and displacement, and the international community’s failure to prioritise human rights in its dealings both with Bangladesh and with Myanmar. Puttanee Kangkun and John Quinley document the persistent persecution and denial of rights the Rohingya have faced for decades. Jeff Crisp reflects on the premature, involuntary and unsafe return of Rohingya refugees to Myanmar in the 1970s and 1990s, and asks whether this could happen again.

Sally Shevach and colleagues explore how the ‘localisation’ agenda has influenced the operational response, and Kerrie Holloway draws on research by the Humanitarian Policy Group to test the common assumption that local actors necessarily have a better understanding of people’s needs. Nasif Rashad Khan and colleagues and Ashish Banik reflect on their experiences of engaging with the international humanitarian response system. Margie Buchanan-Smith and Marian Casey-Maslen discuss evaluation findings relating to communication and community engagement, a theme taken up by Nick Van Praag and Kai Hopkins, who report on a Ground Truth survey on refugees’ perceptions of assistance. Julia Brothwell discusses the British Red Cross/Bangladesh Red Crescent involvement in disaster preparedness and risk reduction during the monsoon season, and Gina Bark, Kate White and Amelie Janon outline the consequences of long-term exclusion from basic healthcare services in increasing vulnerability to preventable diseases. Matthew Wencel and colleagues round off the issue with reflections on data collection coordination and other challenges associated with monitoring large concentrations of refugees.

 

 

Reasons for Lack of HPV Vaccine Initiation in NIS-Teen Over Time: Shifting the Focus From Gender and Sexuality to Necessity and Safety

Journal of Adolescent Health
November 2018 Volume 63, Issue 5, p519-662
https://www.jahonline.org/issue/S1054-139X(17)X0026-8

Adolescent Health Briefs
Reasons for Lack of HPV Vaccine Initiation in NIS-Teen Over Time: Shifting the Focus From Gender and Sexuality to Necessity and Safety
Anna Beavis, Melinda Krakow, Kimberly Levinson, Anne F. Rositch
p652–656
Published in issue: November 2018

 

 

Enhancing Immunization Rates at Aurora Family Medicine Clinics in Milwaukee, Wisconsin

Journal of Patient-Centered Research and Reviews
Volume 5, Issue 4 (2018)
https://digitalrepository.aurorahealthcare.org/jpcrr/

Patient Self-Management
Enhancing Immunization Rates at Aurora Family Medicine Clinics in Milwaukee, Wisconsin
Zeeshan A. Yacoob, Christopher Cook, Jessica J.F. Kram, Marianne Klumph, Dennis J. Baumgardner, Marisa Stanley, Paul Hunter, and Fabiana Kotovicz

Experiences With Medical Exemptions After a Change in Vaccine Exemption Policy in California

Pediatrics
November 2018, VOLUME 142 / ISSUE 5
http://pediatrics.aappublications.org/content/142/5?current-issue=y

Articles
Experiences With Medical Exemptions After a Change in Vaccine Exemption Policy in California
Salini Mohanty, Alison M. Buttenheim, Caroline M. Joyce, Amanda C. Howa, Daniel Salmon, Saad B. Omer
Pediatrics Nov 2018, 142 (5) e20181051; DOI: 10.1542/peds.2018-1051
On the basis of semistructured interviews with health officers and immunization staff, we described their experiences with SB277, which eliminated nonmedical vaccine exemptions in California.

Vaccination and Risk of Childhood IgA Vasculitis

Pediatrics
November 2018, VOLUME 142 / ISSUE 5
http://pediatrics.aappublications.org/content/142/5?current-issue=y

Vaccination and Risk of Childhood IgA Vasculitis
Maryam Piram, Solange Gonzalez Chiappe, Fouad Madhi, Tim Ulinski, Alfred Mahr
Pediatrics Nov 2018, 142 (5) e20180841; DOI: 10.1542/peds.2018-0841
In this study, we discuss the risk of developing pediatric IgAV (Henoch–Schönlein purpura) in the 3 months after vaccinations.
 

Estimation of Pneumonic Plague Transmission in Madagascar, August–November 2017

PLoS Currents: Outbreaks
http://currents.plos.org/outbreaks/
[Accessed 3 Nov 2018 ]

Estimation of Pneumonic Plague Transmission in Madagascar, August–November 2017
November 1, 2018 · Discussion
Introduction: Between August and November 2017, Madagascar reported nearly 2500 cases of plague; the vast majority of these cases were pneumonic, resulting in early exponential growth due to person-to-person transmission. Though plague is endemic in Madagascar, cases are usually bubonic and thus result in considerably smaller annual caseloads than those observed from August–November 2017.
Methods: In this study, we consider the transmission dynamics of pneumonic plague in Madagascar during this time period, as well as the role of control strategies that were deployed to curb the outbreak and their effectiveness.
Results: When using data from the beginning of the outbreak through late November 2017, our estimates for the basic reproduction number range from 1.6 to 3.6, with a mean of 2.4. We also find two distinctive periods of “control”, which coincide with critical on-the-ground interventions, including contact tracing and delivery of antibiotics, among others.
Discussion: Given these results, we conclude that existing interventions remain effective against plague in Madagascar, despite the atypical size and spread of this particular outbreak.

Reported willingness to participate in a hypothetical HIV vaccine trial and its translation to actual participation among healthy adults—Experience from Kenya

PLoS One
http://www.plosone.org/
[Accessed 3 Nov 2018 ]

Research Article
Reported willingness to participate in a hypothetical HIV vaccine trial and its translation to actual participation among healthy adults—Experience from Kenya
Delvin Kwamboka Nyasani, Gaudensia Nzembi Mutua, Rose Miroyo Sajabi, Jane Wairimu Ng’ang’a, John Ndungu Gachie, Amos Macharia Maina, Laura Lunani Lusike, Aggrey Omu Anzala, Matthew A. Price, Gloria Omosa Manyonyi

| published 02 Nov 2018 PLOS ONE

Reported willingness to participate in a hypothetical HIV vaccine trial and its translation to actual participation among healthy adults—Experience from Kenya

PLoS One
http://www.plosone.org/
[Accessed 3 Nov 2018 ]

Research Article
Reported willingness to participate in a hypothetical HIV vaccine trial and its translation to actual participation among healthy adults—Experience from Kenya
Delvin Kwamboka Nyasani, Gaudensia Nzembi Mutua, Rose Miroyo Sajabi, Jane Wairimu Ng’ang’a, John Ndungu Gachie, Amos Macharia Maina, Laura Lunani Lusike, Aggrey Omu Anzala, Matthew A. Price, Gloria Omosa Manyonyi

| published 02 Nov 2018 PLOS ONE

Factors affecting complete and timely childhood immunization coverage in Sindh, Pakistan; A secondary analysis of cross-sectional survey data

PLoS One
http://www.plosone.org/
[Accessed 3 Nov 2018 ]

Factors affecting complete and timely childhood immunization coverage in Sindh, Pakistan; A secondary analysis of cross-sectional survey data
Jin-Won Noh, Young-mi Kim, Nabeel Akram, Ki-Bong Yoo, Jumin Park, Jooyoung Cheon, Young Dae Kwon, Jelle Stekelenburg
Research Article | published 31 Oct 2018 PLOS ONE
https://doi.org/10.1371/journal.pone.0206766

Integrating emergency risk communication (ERC) into the public health system response: Systematic review of literature to aid formulation of the 2017 WHO Guideline for ERC policy and practice

PLoS One
http://www.plosone.org/
[Accessed 3 Nov 2018 ]

Integrating emergency risk communication (ERC) into the public health system response: Systematic review of literature to aid formulation of the 2017 WHO Guideline for ERC policy and practice
Ayan Jha, Leesa Lin, Sarah Massin Short, Giorgia Argentini, Gaya Gamhewage, Elena Savoia
Research Article | published 31 Oct 2018 PLOS ONE
https://doi.org/10.1371/journal.pone.0205555

 

Emergency Department Response to Chemical, Biological, Radiological, Nuclear, and Explosive Events: A Systematic Review

Prehospital & Disaster Medicine
Volume 33 – Issue 5 – October 2018
https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue

Comprehensive Review
Emergency Department Response to Chemical, Biological, Radiological, Nuclear, and Explosive Events: A Systematic Review
Saydia Razak, Sue Hignett, Jo Barnes
https://doi.org/10.1017/S1049023X18000900
Published online: 31 October 2018, pp. 543-549

Florida physicians’ reported use of AFIX-based strategies for human papillomavirus vaccination

Preventive Medicine
Volume 116  Pages 1-226 (November 2018)
https://www.sciencedirect.com/journal/preventive-medicine/vol/116/suppl/C

Research article  Abstract only
Florida physicians’ reported use of AFIX-based strategies for human papillomavirus vaccination
Monica L. Kasting, Shannon M. Christy, Steven K. Sutton, Paige Lake, … Susan T. Vadaparampil
Pages 143-149

Media/Policy Watch

Media/Policy Watch

This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. Media Watch is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from Journal Watch above which scans the peer-reviewed journal ecology.

We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.

 
 
The Atlantic
http://www.theatlantic.com/magazine/
Accessed 3 Nov 2018  
[No new, unique, relevant content]
 
 
BBC
http://www.bbc.co.uk/
Accessed 3 Nov 2018  
[No new, unique, relevant content]
 
 
The Economist
http://www.economist.com/
Accessed 3 Nov 2018  
[No new, unique, relevant content]
 
 
Financial Times
http://www.ft.com/home/uk
Accessed 3 Nov 2018  
[No new, unique, relevant content]
 
 
Forbes
http://www.forbes.com/
Accessed 3 Nov 2018
[No new, unique, relevant content]
 
 
Foreign Affairs
http://www.foreignaffairs.com/
Accessed 3 Nov 2018  
[No new, unique, relevant content]
 
 
Foreign Policy
http://foreignpolicy.com/
Accessed 3 Nov 2018  
[No new, unique, relevant content]
 
 
The Guardian
http://www.guardiannews.com/
Accessed 3 Nov 2018
[No new, unique, relevant content]
 
 
New Yorker
http://www.newyorker.com/
Accessed 3 Nov 2018
[No new, unique, relevant content]
 
 
New York Times
http://www.nytimes.com/
Accessed 3 Nov 2018
Middle East
Israel Battles Measles Outbreak as Infant Dies of Disease
Israel is grappling with one of its worst measles outbreak in decades, with over 1,200 cases reported since the beginning of 2018.
 
In Congo’s Ebola Outbreak, Experimental Treatments Are Proving Effective
31 October 2018
 
 
Anti-Vaccine Billboards Appear in Several US States
29 October 2018
 
 
Wall Street Journal
http://online.wsj.com/home-page?_wsjregion=na,us&_homepage=/home/us
Accessed 3 Nov 2018
Latin America
Venezuela’s Health Crisis Is Crossing the Border
By Juan Forero, Luciana Magalhaes
Oct. 31, 2018 10:54 am ET
Desperate refugees spread malaria, yellow fever, diphtheria, dengue and tuberculosis to neighboring countries as health-care system implodes.
 
 
Washington Post
http://www.washingtonpost.com/
Accessed 3 Nov 2018
[No new, unique, relevant content]

Vaccines and Global Health: The Week in Review :: 27 October 2018

.– Request an Email Summary: Vaccines and Global Health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

 pdf version A pdf of the current issue is available here: Vaccines and Global Health_The Week in Review_27 Oct 2018

– blog edition: comprised of the approx. 35+ entries posted below.

– Twitter:  Readers can also follow developments on twitter: @vaxethicspolicy.
.
– Links:  We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy

Declaration of Astana :: Declaration of Astana

Milestones :: Perspectives

Declaration of Astana

Global Conference on Primary Health Care
From Alma-Ata towards universal health coverage and the Sustainable Development Goals
Astana, Kazakhstan, 25 and 26 October 2018
12 pages  :: pdf: https://www.who.int/docs/default-source/primary-health/declaration/gcphc-declaration.pdf
[Excerpts]
We, Heads of State and Government, ministers and representatives of States and Governments1, participating in the Global Conference on Primary Health Care: From Alma-Ata towards universal health coverage and the Sustainable Development Goals, meeting in Astana on 25 and 26 October 2018, reaffirming the commitments expressed in the ambitious and visionary Declaration of Alma-Ata of 1978 and the 2030 Agenda for Sustainable Development, in pursuit of Health for All, hereby make the following Declaration.

We envision

Governments and societies that prioritize, promote and protect people’s health and well-being, at both population and individual levels, through strong health systems;

Primary health care and health services that are high quality, safe, comprehensive, integrated, accessible, available and affordable for everyone and everywhere, provided with compassion, respect and dignity by health professionals who are well-trained, skilled, motivated and committed;

Enabling and health-conducive environments in which individuals and communities are empowered and engaged in maintaining and enhancing their health and well-being;

Partners and stakeholders aligned in providing effective support to national health policies, strategies and plans.

I
We strongly affirm our commitment to the fundamental right of every human being to the enjoyment of the highest attainable standard of health without distinction of any kind. Convening on the fortieth anniversary of the Declaration of Alma-Ata, we reaffirm our commitment to all its values and principles, in particular to justice and solidarity, and we underline the importance of health for peace, security and socioeconomic development, and their interdependence.

II
We are convinced that strengthening primary health care (PHC) is the most inclusive, effective and efficient approach to enhance people’s physical and mental health, as well as social well-being, and that PHC is a cornerstone of a sustainable health system for universal health coverage (UHC) and health-related Sustainable Development Goals. We welcome the convening in 2019 of the United Nations General Assembly high-level meeting on UHC, to which this Declaration will contribute. We will each pursue our paths to achieving UHC so that all people have equitable access to the quality and effective health care they need, ensuring that the use of these services does not expose them to financial hardship.

III.
…Promotive, preventive, curative, rehabilitative services and palliative care must be accessible to all. We must save millions of people from poverty, particularly extreme poverty, caused by disproportionate out-of-pocket spending on health. We can no longer underemphasize the crucial importance of health promotion and disease prevention, nor tolerate fragmented, unsafe or poor-quality care. We must address the shortage and uneven distribution of health workers. We must act on the growing costs of health care and medicines and vaccines. We cannot afford waste in health care spending due to inefficiency….

  1. Build sustainable primary health care

PHC will be implemented in accordance with national legislation, contexts and priorities. We will strengthen health systems by investing in PHC. We will enhance capacity and infrastructure for primary care – the first contact with health services – prioritizing essential public health functions. We will prioritize disease prevention and health promotion and will aim to meet all people’s health needs across the life course through comprehensive preventive, promotive, curative, rehabilitative services and palliative care. PHC will provide a comprehensive range of services and care, including but not limited to vaccination; screenings; prevention, control and management of noncommunicable and communicable diseases; care and services that promote, maintain and improve maternal, newborn, child and adolescent health; and mental health and sexual and reproductive health2. PHC will also be accessible, equitable, safe, of high quality, comprehensive, efficient, acceptable, available and affordable, and will deliver continuous, integrated services that are people-centred and gender-sensitive. We will strive to avoid fragmentation and ensure a functional referral system between primary and other levels of care. We will benefit from sustainable PHC that enhances health systems’ resilience to prevent, detect and respond to infectious diseases and outbreaks…

 

News Release

New global commitment to primary health care for all at Astana conference

Declaration of Astana charts course to achieve universal health coverage, 40 years since declaration on primary health care in Alma-Ata

25 October 2018, Astana, Kazakhstan

Countries around the world today agreed to the Declaration of Astana, vowing to strengthen their primary health care systems as an essential step toward achieving universal health coverage. The Declaration of Astana reaffirms the historic 1978 Declaration of Alma-Ata, the first time world leaders committed to primary health care.

“Today, instead of health for all, we have health for some,” said Dr. Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization (WHO). “We all have a solemn responsibility to ensure that today’s declaration on primary health care enables every person, everywhere to exercise their fundamental right to health.”

While the 1978 Declaration of Alma-Ata laid a foundation for primary health care, progress over the past four decades has been uneven. At least half the world’s population lacks access to essential health services – including care for noncommunicable and communicable diseases, maternal and child health, mental health, and sexual and reproductive health.

“Although the world is a healthier place for children today than ever before, close to 6 million children die every year before their fifth birthday mostly from preventable causes, and more than 150 million are stunted,” said Henrietta Fore, UNICEF Executive Director. “We as a global community can change that, by bringing quality health services close to those who need them. That’s what primary health care is about.”

The Declaration of Astana comes amid a growing global movement for greater investment in primary health care to achieve universal health coverage. Health resources have been overwhelmingly focused on single disease interventions rather than strong, comprehensive health systems – a gap highlighted by several health emergencies in recent years.

“Adoption of the Declaration at this global conference in Astana will set new directions for the development of primary health care as a basis of health care systems,” said Yelzhan Birtanov, Minister of Health of the Republic of Kazakhstan. “The new Declaration reflects obligations of countries, people, communities, health care systems and partners to achieve healthier lives through sustainable primary health care.”

UNICEF and WHO will help governments and civil society to act on the Declaration of Astana and encourage them to back the movement. UNICEF and WHO will also support countries in reviewing the implementation of this Declaration, in cooperation with other partners.

Notes to editors:

The Global Conference on Primary Health Care is taking place from 25-26 October in Astana, Kazakhstan, co-hosted by WHO, UNICEF and the Government of Kazakhstan. Participants include ministers of health, finance, education and social welfare; health workers and patient advocates; youth delegates and activists; and leaders representing bilateral and multilateral institutions, global health advocacy organizations, civil society, academia, philanthropy, media and the private sector.

The Declaration of Astana, unanimously endorsed by all WHO Member States, makes pledges in four key areas: (1) make bold political choices for health across all sectors; (2) build sustainable primary health care; (3) empower individuals and communities; and (4) align stakeholder support to national policies, strategies and plans.

 

 

UNICEF Airlifts 4.7 Million Doses of Measles, Rubella and Polio Vaccines for Children in Libya

Libya

UNICEF Airlifts 4.7 Million Doses of Measles, Rubella and Polio Vaccines for Children in Libya

Press release

TRIPOLI, 25 October 2018 – The third UNICEF-chartered plane has arrived at Mitiga airport, Tripoli, completing the delivery of a total 4.7 million doses of Measles, Rubella and Polio vaccines, as well as 2.75 million doses of Vitamin ‘A’ supplement, syringes and safety boxes. These supplies will be essential in Libya’s National Vaccination Campaign run in coordination with the World Health Organization [WHO] taking place at the end of November, which aims to protect some 2.75 million children at risk of vaccine-preventable diseases.

The current protracted conflict in Libya has resulted in damage to health infrastructure, disruption of public health services and access to basic health care. Limited investment in the health system has severely affected childhood vaccination, among other essential programmes.

Compounded by the desperate situation of migrants using Libya as a transit point, many of whom have not received immunizations in their country of origin or missed the required dose in Libya, routine immunization services in Libya have not been sufficient. Evidence shows that a number of boys and girls, particularly among the migrant communities and those living in hard-to-reach and conflict-affected areas of the country, have not been vaccinated.

“Deadly diseases such as measles don’t discriminate. They can hit any vulnerable child, anywhere. We are working closely with the Libyan authorities to ensure that the lifesaving vaccines are available across the country, including in hard to reach areas. Being vaccinated is every child’s right”, said Abdel-Rahman Ghandour, UNICEF Special Representative to Libya.

“The recent Measles outbreak and the existing risk of importation of poliovirus makes it very important to increase the immunity of the children against these diseases. WHO and UNICEF joining hands in conducting a national campaign for Measles and Polio is the most strategic approach to pre-empt major outbreaks as well as targeting migrant children”, said Dr Syed Jaffar Hussein, WHO Representative and Head of Mission, Libya.

UNICEF, WHO and the United Nations Central Emergency Response Fund (CERF) have allocated US$5.0 million to conduct a nationwide measles outbreak response immunization, vaccination against polio and vitamin A supplementation. The campaign will be run in partnership with the Ministry of Health – Center for National Disease Control, WHO, IOM and UNHCR.

NEW REPORT: The State of Vaccine Confidence in the EU: 2018

NEW REPORT: The State of Vaccine Confidence in the EU: 2018

Heidi Larson | 26 Oct, 2018
Confidence Commentary: Vaccine Confidence Project
High confidence in vaccination programmes is crucial for maintaining high coverage rates, especially at levels that exceed those required for herd immunity. Across the European Union (EU), however, vaccine delays and refusals are contributing to declining immunisation rates in a number of countries and are leading to increases in disease outbreaks. Recent measles outbreaks – the highest in the EU for seven years – illustrate the immediate impact of declining coverage on disease outbreaks.

In this report  we assess the overall state of confidence in vaccines among the public in all 28 EU member states and among general practitioners (GP) in ten EU member states. As vaccine confidence varies by vaccine, confidence is assessed for vaccines in general as well as for the measles and seasonal influenza vaccines, in order to reflect vaccines targeting different population groups. Confidence in (and demand for) vaccines is influenced by a number of factors, including the importance, safety, and effectiveness of vaccines. To examine the extent of public and GP confidence in vaccines, we have conducted the largest ever study on attitudes to vaccines and vaccination in the EU. We find a range of novel EU-wide and country-specific insights into vaccination behaviours that may immediately impact on public policy.

We report a number of key findings. We find that younger adults in the survey have less confidence in the safety and importance of both the MMR and seasonal influenza vaccines (and vaccines generally) than older age groups. The results of the survey suggest that a number of member states – including France, Greece, Italy, and Slovenia – have become more confident in the safety of vaccines since 2015; while Czech Republic, Finland, Poland, and Sweden have become less confident over the same period. While GPs generally hold higher levels of vaccine confidence than the public, 7 the survey found that 36% of GPs surveyed in Czech Republic and 25% in Slovakia do not agree that the MMR vaccine is safe and 29% and 19% (respectively) do not believe it is important. We find that the majority of GPs surveyed in these countries report that they are not likely to recommend the seasonal influenza vaccine, yet Czech Republic, Poland, and Slovakia all report to the WHO that they recommend the seasonal influenza vaccine to pregnant women (WHO, Immunization Schedule by Antigens, 2018).

More information on the European Commission vaccination policy can be found here.

 

 

IAVI and Serum Institute of India to Develop and Manufacture Globally Affordable and Accessible Antibody Products for HIV

IAVI and Serum Institute of India to Develop and Manufacture Globally Affordable and Accessible Antibody Products for HIV

NEW YORK – October 22, 2018 – The International AIDS Vaccine Initiative (IAVI) and Serum Institute of India, the world’s largest vaccine manufacturer, today announced a strategic partnership to develop and manufacture affordable and accessible monoclonal antibody products for HIV and other global health challenges.

“IAVI is committed to translating scientific innovation into public health solutions, and we are collaborating with Serum Institute to enable global access to broadly neutralizing monoclonal antibodies (bNAbs) against HIV, if they are proven effective at preventing HIV infection. Through this partnership, we will work to pioneer a viable and sustainable pathway toward accessible, low-cost, antibody-based products for HIV, which if successful, may also be applied more broadly to innovative monoclonal antibody therapeutics targeting other disease areas,” said Mark Feinberg, M.D., Ph.D., president and CEO, IAVI.

“We have a proven record of developing and delivering vaccines and pharmaceutical products globally, and we are already applying this expertise in the field of antibody development. I am extremely pleased that Serum Institute and IAVI have joined forces in the fight against HIV with the aim of making cost-effective monoclonal antibodies for HIV, and in the fields of antimicrobial resistance and anti-snake venom. Provided the breadth of our technology, I am confident that we will be able to make positive contributions in these important areas,” said Adar Poonawalla, CEO, Serum Institute of India. “Monoclonal antibodies are providing significant therapeutic benefit in the treatment of a growing number of serious diseases. However, due to their high cost, the availability of current products is limited to wealthier countries. In light of the demonstrated efficacy of monoclonal antibodies and their future promise as globally relevant tools for disease treatment and prevention, this must change. Serum Institute is committed to developing high quality, affordable, monoclonal antibodies with the potential to treat and prevent HIV and other diseases in India and across the globe.”..

 

Ebola virus disease – Democratic Republic of the Congo :: 12: Situation report on the Ebola outbreak in North Kivu 

Milestones :: Perspectives

Ebola – Democratic Republic of the Congo

Ebola virus disease – Democratic Republic of the Congo   
25 October 2018
Public Health Response
…Vaccination:
As of 24 October, 122 vaccination rings have been defined, in addition to 37 rings of health and frontline workers. To date, 22 288 eligible and consented people have been vaccinated, including 8471 health and frontline workers and 5488 children. Overall, vaccination teams have reached an additional 3345 eligible and consenting people in the past week…

12: Situation report on the Ebola outbreak in North Kivu 
23 October 2018
Situation Update
… Since WHO’s last situation report issued on 17 October 2018 (External Situation Report 11), an additional 22 new confirmed EVD cases, from Beni (19) and Butembo (3), and 16 new deaths have been reported. As of 21 October 2018, a total of 238 confirmed and probable EVD cases, including 155 deaths, have been reported, resulting in a case fatality ratio (CFR) of 65%. Among the 238 cases, 203 are confirmed and 35 are probable cases. Of the 155 deaths reported since the beginning of the outbreak, 120 were among confirmed cases and 35 among probable cases. The proportion of deaths among confirmed cases was 59% (120/203). On 21 October, 14 new suspected cases were under investigation in Beni (8), Mabalako (1), Butembo (2) and Mandima (3).
As of 21 October 2018, 63 cases have recovered, been discharged from ETCs, and re-integrated into their communities. On 21 October, a total of 60 cases remained hospitalized in four ETCs in Beni (38), Butembo (19), Mangina (two) and Makeke (one). On that day, the treatment centres in Beni and Butembo recorded an occupancy rate of 93% (38/41) and 79% (19/24) respectively…
Case management
Ebola Treatment Centres (ETCs) continue to provide therapeutics under the monitored emergency use of unregistered and experimental interventions (MEURI) protocol, in collaboration with the MoH and the Institut National de Recherche Biomédicale (INRB) together with supportive care measures. WHO is providing technical clinical expertise on-site and is assisting with the creation of a data safety management board…

Emergencies

Emergencies
 
 
POLIO
Public Health Emergency of International Concern (PHEIC)
Polio this week as of 23 October 2018 [GPEI]
:: World Polio Day activities are in full swing.  Join partners around the world in raising awareness about the global effort to eradicate polio.

Summary of new viruses this week:
Afghanistan – one wild poliovirus type 1 (WPV1) positive environmental sample;
Pakistan – two WPV1 cases and four WPV1-positive environmental samples;
Nigeria – one cVDPV2 case and three cVDPV2-positive environmental samples

::::::
::::::
 
Editor’s Note:
WHO has posted a refreshed emergencies page which presents an updated listing of Grade 3,2,1 emergencies as below.
 
 
 WHO Grade 3 Emergencies  [to 27 Oct 2018 ]
Democratic Republic of the Congo
:: Beni: Ministry of Health and WHO condemn violence against civilians and health professionals in Ebola affected areas [in French]  22 October 2018
:: 12: Situation report on the Ebola outbreak in North Kivu  23 October 2018
:: Ebola virus disease – Democratic Republic of the Congo   25 October 2018
[See Milestones above for more detail]
 
Bangladesh – Rohingya crisis
:: Weekly Situation Report 47 – 17 October 2018
 
Nigeria – No new announcements identified
Somalia – No new announcements identified
South Sudan – No new announcements identified
Syrian Arab Republic – No new announcements identified
Yemen – No new announcements identified

::::::
 
WHO Grade 2 Emergencies  [to 27 Oct 2018 ]
Brazil (in Portugese) – No new announcements identified
Cameroon  – No new announcements identified
Central African Republic  – No new announcements identified
Ethiopia – No new announcements identified
Hurricane Irma and Maria in the Caribbean – No new announcements identified
Iraq – No new announcements identified
occupied Palestinian territory – No new announcements identified
Libya – No new announcements identified
MERS-CoV – No new announcements identified
Myanmar – No new announcements identified
Niger – No new announcements identified
Sao Tome and Principe Necrotizing Cellulitis (2017) – No new announcements identified
Sudan – No new announcements identified
Ukraine – No new announcements identified
Zimbabwe – No new announcements identified
 
 
Outbreaks and Emergencies Bulletin, Week 42: 13-19 October 2018

The WHO Health Emergencies Programme is currently monitoring 55 events in the region. This week’s edition covers key ongoing events, including:
:: Ebola virus disease outbreak in the Democratic Republic of the Congo
:: Dengue Fever in Senegal
:: Hepatitis E in Namibia
:: Cholera in Zimbabwe.

::::::
 
WHO Grade 1 Emergencies  [to 27 Oct 2018 ]
Afghanistan
Angola (in Portuguese)
Chad
Ethiopia
Kenya
Lao People’s Democratic Republic
Mali
Papua New Guinea
Peru
Tanzania
Tropical Cyclone Gira
Zambia
 
::::::
 
UN OCHA – L3 Emergencies
The UN and its humanitarian partners are currently responding to three ‘L3’ emergencies. This is the global humanitarian system’s classification for the response to the most severe, large-scale humanitarian crises. 
Yemen
:: Yemen Humanitarian Update Covering 7 October – 21 October …
:: Yemen: Cyclone Luban Flash Update #3 (21 October 2018) [EN/A …

Syrian Arab Republic   No new announcements identified.

::::::

UN OCHA – Corporate Emergencies
When the USG/ERC declares a Corporate Emergency Response, all OCHA offices, branches and sections provide their full support to response activities both at HQ and in the field.
Ethiopia  No new announcements identified.
Somalia  No new announcements identified.
 
::::::

“Other Emergencies”
Indonesia: Central Sulawesi Earthquake
:: Central Sulawesi Earthquake & Tsunami: Humanitarian Country Team Situation Report #5 (as of 23 October 2018)

::::::
::::::
 
Editor’s Note:
We will cluster these recent emergencies as below and continue to monitor the WHO webpages for updates and key developments.

EBOLA/EVD  [to 27 Oct 2018 ]
http://www.who.int/ebola/en/
[See Milestones above for more detail]

MERS-CoV [to 27 Oct 2018 ]
http://who.int/emergencies/mers-cov/en/
No new announcements identified.
 
Yellow Fever  [to 27 Oct 2018 ]
http://www.who.int/csr/disease/yellowfev/en/
No new announcements identified.
 
Zika virus  [to 27 Oct 2018 ]
http://www.who.int/csr/disease/zika/en/
No new announcements identified.
 
::::::
::::::
 
WHO & Regional Offices [to 27 Oct 2018 ]
25 October 2018
News Release
New global commitment to primary health care for all at Astana conference
Declaration of Astana charts course to achieve universal health coverage, 40 years since declaration on primary health care in Alma-Ata
[See Milestones/Perspectives above for more detail]

23 October 2018
News Release
HH Pope Francis and WHO Director-General: Health is a right and not a privilege

::::::
 
Weekly Epidemiological Record, 26 October 2018, vol. 93, 43 (pp. 577–588)
:: Joint external evaluation of implementation of the International Health Regulations (2005) in Libya: a bridge to safeguard nationals
:: Update on vaccine-derived polioviruses – worldwide, January 2017–June 2018

::::::
 
WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region AFRO
Selected Featured News
:: Uganda’s Prime Minister lauds WHO for the support during disease outbreak emergencies
26 October 2018
:: Protecting girls against cervical cancer in Tanzania  24 October 2018

:: Joint Statement on World Polio Day: WHO, UNICEF and Rotary International reaffirm their commitments to stop off polio in the Horn of Africa. 24 October 2018
:: Polio infrastructure remains crucial for mounting initial response to disease outbreaks in Nigeria   23 October 2018

WHO Region of the Americas PAHO
:: New global commitment to Primary Health Care for all at Astana Conference (10/25/2018)
:: Countries of the Americas urged to take action to keep polio at bay (10/23/2018)
 
WHO South-East Asia Region SEARO
– No new announcement identified
 
WHO European Region EURO
:: Social marketing insights help solve the puzzle of low influenza vaccination rates among health-care workers in the west of Ireland 26-10-2018
:: New global commitment to primary health care for all at Astana conference 26-10-2018
:: Primary health care: the time is now 24-10-2018
:: World Polio Day celebrates history in the making 23-10-2018
:: Is it just a “touch of the flu” for you, or do you face a greater risk? 22-10-2018

WHO Eastern Mediterranean Region EMRO
:: Pool of experts for Middle East respiratory syndrome established  23 October 2018
:: Contribution of United Arab Emirates acknowledged on World Polio Day  23 October 2018
:: HH Pope Francis and WHO Director-General: Health is a right and not a privilege 23 October 2018
:: Health system strengthening boosts immunization in Somalia  22 October 2018

WHO Western Pacific Region
– No new announcement identified
 
 

CDC/ACIP [to 27 Oct 2018 ]

CDC/ACIP [to 27 Oct 2018 ]

http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html
MMWR News Synopsis for October 26, 2018
Influenza A(H3N2) Variant Virus Outbreak at Three Fairs — Maryland, 2017
People at high risk for serious influenza complications should avoid pigs and swine barns because of the risk of contracting a variant type of influenza that circulates in pigs. In 2017, an outbreak of variant influenza – human infection with influenza viruses that normally circulate in swine – was detected in Maryland. Influenza A(H3N2) variant virus infection was identified in 40 patients with exposure to swine at one of three Maryland agricultural fairs. More than one-third (35%) of patients reported only indirect contact with swine. Sixty percent of patients were children younger than 5 years. Three-fourths of these patients were at high risk for serious influenza complications (age <5 or ≥65 years, or a chronic medical condition). This outbreak highlights the risk, particularly among children, for contracting variant influenza virus at agricultural fairs, and underscores the need for increased public awareness that people in high-risk groups should avoid pigs and swine barns.

Update: Influenza Activity — United States and Worldwide, May 20–October 13, 2018
CDC recommends yearly influenza vaccination for everyone 6 months of age and older without contraindications. CDC recommends getting vaccinated by the end of October; however, vaccination should continue throughout the influenza season as long as influenza viruses are circulating. While annual influenza vaccination is the best way to prevent influenza and its potentially serious complications, prescription influenza antiviral medications can be used to treat influenza illness. Early treatment is recommended for patients with influenza illness who are very sick or who are sick and at high risk for influenza complications. Antiviral medications can shorten the duration and severity of illness and help prevent more severe illness; they work best when started within 48 hours of symptom onset. This article summarizes influenza activity in the U.S. and globally from May 20 through October 13, 2018. While influenza A (H1N1)pdm09, influenza A (H3N2) and influenza B viruses were identified, influenza A(H1N1) predominated in the U.S. and globally in most regions. Summertime influenza activity in the United States has been low and influenza activity in the Southern Hemisphere during their influenza season has been relatively low and fairly mild. Antigenic testing of available influenza A and B viruses has not detected significant antigenic drift in circulating viruses. It is difficult to predict which influenza virus will predominate or how severe influenza disease activity will be during the 2018-2019 influenza season.

Measles Outbreak in a Highly Vaccinated Population — Israel, July–August 2017
In outbreak settings, health care providers should maintain a high index of suspicion for measles, regardless of vaccination status, and conduct a thorough epidemiologic and laboratory investigation of suspected measles cases. During the summer of 2017, nine measles cases occurred among vaccinated Israeli soldiers. The primary case had recently traveled to Europe. All other cases were his direct contacts. All patients had mild illness; no tertiary cases occurred. Unlike most previous outbreaks in Israel, which occurred in unvaccinated or partially vaccinated populations, this outbreak occurred in a population with high two-dose measles vaccination coverage. Because of the mild symptoms, without active surveillance the possibility of measles would likely not have been considered and circulation of the virus might have continued. The fact that most contacts were fully vaccinated probably contributed to rapid containment.

Update on Vaccine-Derived Polioviruses — Worldwide, January 2017–June 2018
Vaccine-derived polioviruses will continue to cause rare outbreaks and infect individuals with immunodeficiency until all use of oral poliovirus vaccine can cease after wild poliovirus transmission is eradicated. All countries must maintain high population immunity to polio through vaccination. Vaccine-derived polioviruses (VDPVs) are strains genetically divergent from the oral poliovirus vaccine (OPV) that fall into three categories: 1) circulating VDPVs (cVDPVs) from outbreaks, 2) immunodeficiency-associated VDPVs (iVDPVs) from patients with primary immunodeficiencies, and 3) ambiguous VDPVs (aVDPVs) that cannot be more definitively identified. During January 2017–June 2018, new cVDPV outbreaks were identified in the Democratic Republic of the Congo, Kenya, Nigeria, Papua New Guinea, Somalia, and Syria. Six newly identified persons in four countries were found to excrete iVDPVs.

 

China CDC  :: National Health Commission of the People’s Republic of China

China CDC 
http://www.chinacdc.cn/en/
New website launched…no “news” or “announcements” page identified.

National Health Commission of the People’s Republic of China
http://en.nhfpc.gov.cn/
Selected Updates/Press Releases

Premier Li urges price reduction on cancer drugs
2018-10-26
The government will make efforts to reduce the cost of anti-cancer drugs, and ease the suffering of patients and their finance burdens, said Premier Li Keqiang on Oct 24.

Draft law takes aim at fake drugs
2018-10-23
People who produce and sell medicines illegally in China could face heavier penalties under a draft amendment to intensify supervision to protect public health.

Announcements

Announcements
 
 
BMGF – Gates Foundation  [to 27 Oct 2018 ]
http://www.gatesfoundation.org/Media-Center/Press-Releases
No new digest content identified.
 
 
Bill & Melinda Gates Medical Research Institute    [to 27 Oct 2018]
https://www.gatesmri.org/
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.
 
 
CARB-X   [to 27 Oct 2018 ]
https://carb-x.org/
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
No new digest content identified.
 
 
CEPI – Coalition for Epidemic Preparedness Innovations  [to 27 Oct 2018 ]
http://cepi.net/
No new digest content identified.
 
 
EDCTP    [to 27 Oct 2018 ]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
No new digest content identified.
 
 
Emory Vaccine Center    [to 27 Oct 2018 ]
http://www.vaccines.emory.edu/
No new digest content identified.
 
 
European Medicines Agency  [to 27 Oct 2018 ]
http://www.ema.europa.eu/ema/
News and press releases
No new digest content identified.
 
 
European Vaccine Initiative  [to 27 Oct 2018 ]
http://www.euvaccine.eu/news-events
No new digest content identified.
 
 
FDA [to 27 Oct 2018 ]
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm
October 23, 2018
FDA launches global operation to crack down on websites selling illegal, potentially dangerous drugs; including opioids

The U.S. Food and Drug Administration, in partnership with international regulatory and law enforcement agencies, acted this week to target 465 websites that illegally sell potentially dangerous, unapproved versions of opioid, oncology and antiviral prescription drugs to U.S. consumers.

This effort was part of Operation Pangea XI, the eleventh annual International Internet Week of Action (IIWA). This is a global cooperative effort, led by Interpol, to combat the unlawful sale and distribution of illegal and potentially counterfeit medical products sold on the internet…
 
 
Fondation Merieux  [to 27 Oct 2018 ]
http://www.fondation-merieux.org/
Mérieux Foundation co-organized event
Case Management working group / Global Task Force on Cholera Control (GTFCC)
November 5 – 6, 2018 – Les Pensieres Center for Global Health, Veyrier-du-Lac (France)
 
Mérieux Foundation co-organized event
Dengue pre-vaccination screening based on serostatus: rapid tests and implementation strategies
January 14 – 16, 2019 – Les Pensières Center for Global Helath, Veyrier du Lac (France)
 
 
Gavi [to 27 Oct 2018 ]
https://www.gavi.org/
No new digest content identified.
 
 
GHIT Fund   [to 27 Oct 2018 ]
https://www.ghitfund.org/newsroom/press
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that devastate the world’s poorest people. Other funders include six Japanese pharmaceutical
No new digest content identified.
 
 
Global Fund [to 27 Oct 2018 ]
News
Gavi and Global Fund Commit to Addressing Sexual Exploitation, Abuse and Harassment
19 October 2018
 
 
Hilleman Laboratories   [to 27 Oct 2018 ]
http://www.hillemanlabs.org/
No new digest content identified.
 
 
Human Vaccines Project   [to 27 Oct 2018 ]
http://www.humanvaccinesproject.org/media/press-releases/
Event
Towards a Universal Influenza Vaccine: Lessons from the Great Influenza Pandemic of 1918 to Now
November 15-16, 2018 I Nashville, TN
The Human Vaccines Project is hosting a scientific summit featuring prominent researchers and thought leaders to discuss cutting-edge influenza research. The 2-day meeting will bring together leading scientists, clinicians and public health specialists including: John Barry, James E. Crowe, Jr., Senator Bill Frist, and Laurie Garrett.  Find a full agenda at:
www.humanvaccinesproject.org/talks/universalinfluenzavaccinesummit
 
 
IAVI  [to 27 Oct 2018 ]
https://www.iavi.org/
October 22, 2018
Antibody-based HIV Prevention: Preparing for Success
New partnership aims to make antibody prophylaxis for HIV more feasible and affordable.
By Mark Feinberg, M.D., Ph.D., President and CEO of IAVI
Among the topics being discussed at the biannual HIV Research for Prevention (R4P) conference now taking place in Madrid, antibodies are at the forefront. Researchers are discussing innovative approaches to induce protective antibodies against HIV by vaccination, as well as the potential for these antibodies to be used directly to prevent HIV infection.
Since 2009, when IAVI scientists and their partners were among the first to identify a new class of HIV-specific antibodies, hundreds of potent antibodies with the ability to neutralize a broad swath of HIV variants have been identified. These so-called broadly neutralizing antibodies (bNAbs) are now reinvigorating efforts to design vaccine immunogens. IAVI and its partners recently advanced one of these immunogens into clinical trials. This candidate was engineered using the latest tools of computational and structural biology by researchers at the IAVI Neutralizing Antibody Center at Scripps Research in La Jolla, California….
 
October 22, 2018
IAVI and Serum Institute of India to Develop and Manufacture Globally Affordable and Accessible Antibody Products for HIV
NEW YORK – October 22, 2018 – The International AIDS Vaccine Initiative (IAVI) and Serum Institute of India, the world’s largest vaccine manufacturer, today announced a strategic partnership to develop and manufacture affordable and accessible monoclonal antibody products for HIV and other global health challenges….
 
 
IFFIm
http://www.iffim.org/library/news/press-releases/
No new digest content identified.
 
 
IVAC  [to 27 Oct 2018 ]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
No new digest content identified.
 
 
IVI   [to 27 Oct 2018 ]
http://www.ivi.int/
No new digest content identified.
 
 
JEE Alliance  [to 27 Oct 2018 ]
https://www.jeealliance.org/
25.10.2018
The Alliance meets to discuss One Health, upcoming work and governance – and invites partners to join the network
Meeting, Advisory Group
Sustainable health security capacity building requires country ownership and a One Health and all hazards approach. The multi-partner Joint External Evaluation (JEE) supports collaboration across sectors such as animal and human health, agriculture, defense, development, environment, food safety, public safety, as well as tourism and trade.
On 5 November 2018, the JEE Alliance will meet in Bali, in the margins of the 5th Global Health Security Agenda Ministerial Meeting hosted by the Government of Indonesia.
The focus of the event will be twofold
:: A panel discussion on facilitating integration of One Health approach in national health security capacity building
:: Discussion on the Alliance work plan and the new Advisory Group for 2019…
 
 
MSF/Médecins Sans Frontières  [to 27 Oct 2018 ]
http://www.msf.org/
Tuberculosis
High prices restrict access to best drug-resistant tuberculosis treatment
Press Release   23 October 2018
MSF calls on US pharma corporation Johnson & Johnson to halve the price of the newer TB drug bedaquiline.
 
 
NIH  [to 27 Oct 2018 ]
http://www.nih.gov/news-events/news-releases
October 23, 2018
NIH selects first scholars in pioneering program to enhance diversity within in-house research program
— Distinguished Scholars Program to augment diversity and inclusion in the biomedical workforce.

October 23, 2018
Amazon Web Services joins NIH’s STRIDES Initiative to harness latest cloud technologies for biomedical researchers
AWS is the second cloud service provider to join the STRIDES Initiative following Google Cloud.
Amazon Web Services (AWS) has joined the National Institutes of Health’s Science and Technology Research Infrastructure for Discovery, Experimentation, and Sustainability (STRIDES) Initiative. Launched in July 2018, the STRIDES Initiative aims to harness the power of commercial cloud computing for NIH biomedical researchers. Initially, NIH’s efforts will focus on making high-value data sets more accessible to researchers and experimenting with new ways to optimize technology-intensive research…
 
 
PATH  [to 27 Oct 2018 ]
https://www.path.org/media-center/
No new digest content identified.
 
 
Sabin Vaccine Institute  [to 27 Oct 2018 ]
http://www.sabin.org/updates/pressreleases
No new digest content identified.
 
 
UNAIDS [to 27 Oct 2018 ]
http://www.unaids.org/en
No new digest content identified.
 
 
UNICEF  [to 27 Oct 2018 ]
https://www.unicef.org/media/press-releases
Selected Press Releases/Reports/Statements
Press release
An estimated 2,300 children traveling with migrant caravan in Mexico need protection and essential services – UNICEF
26/10/2018

Press release
Sulawesi Earthquake & Tsunami: One month on from the disaster, thousands of children still homeless, out-of-school and in need of humanitarian support
26/10/2018

Press release
UNICEF Airlifts 4.7 Million Doses of Measles, Rubella and Polio Vaccines for Children in Libya
25/10/2018

Press release
New global commitment to primary health care for all at Astana conference
Declaration of Astana charts course to achieve universal health coverage, 40 years since declaration on primary health care in Alma-Ata
24/10/2018

Vaccine Confidence Project  [to 27 Oct 2018 ]
http://www.vaccineconfidence.org/
Vaccine Confidence Project – Confidence Commentary
NEW REPORT: The State of Vaccine Confidence in the EU: 2018
Heidi Larson | 26 Oct, 2018
High confidence in vaccination programmes is crucial for maintaining high coverage rates, especially at levels that exceed those required for herd immunity. Across the European Union (EU), however, vaccine delays and refusals are contributing to declining immunisation rates in a number of countries and are leading to increases in disease outbreaks. Recent measles outbreaks – the highest in the EU for seven years – illustrate the immediate impact of declining coverage on disease outbreaks.
In this report  we assess the overall state of confidence in vaccines among the public in all 28 EU member states and among general practitioners (GP) in ten EU member states…
[See Milestones/Perspectives above for detail]
 
 
Vaccine Education Center – Children’s Hospital of Philadelphia  [to 27 Oct 2018 ]
http://www.chop.edu/centers-programs/vaccine-education-center
Vaccine Update for Providers
Newsletter – October 2018
 
 
Wellcome Trust  [to 27 Oct 2018 ]
https://wellcome.ac.uk/news
News / Published: 24 October 2018
Naguib Kheraj to join our Board of Governors
Finance industry leader Naguib Kheraj will join the Wellcome Board of Governors in January 2019.
Naguib Kheraj is Deputy Chairman of Standard Chartered PLC – a major international bank – and Chairman of Rothesay Life, a specialist UK insurer. He is also a current member of Wellcome’s Investment Committee, which is responsible for reviewing and advising on Wellcome’s investment portfolio and strategy…
 
 
The Wistar Institute   [to 27 Oct 2018 ]
https://www.wistar.org/news/press-releases
No new digest content identified.
 
 
World Organisation for Animal Health (OIE)   [to 27 Oct 2018 ]
http://www.oie.int/en/for-the-media/press-releases/2018/
No new digest content identified.

::::::
 
BIO    [to 27 Oct 2018 ]
https://www.bio.org/insights/press-release
No new digest content identified.

 
 
DCVMN – Developing Country Vaccine Manufacturers Network  [to 27 Oct 2018 ]
http://www.dcvmn.org/
29 October 2018 to 31 October 2018
19th DCVMN Annual General Meeting
Kunming / China

WHO prequalifies new rotavirus vaccine
Geneva, 25th September 2018 – The World Health Organization prequalified Rotasil, an oral rotavirus vaccine produced by Serum Institute of India. Rotasil is the first Rotavirus vaccine with heat stable characteristics, which makes it particularly suitable for use in low-income countries, where weak infrastructure and frequent lack of electricity make refrigeration very difficult.
Rotavirus is responsible for about 37% of deaths from diarrhea among children younger than 5 years of age worldwide, with a disproportionate effect in parts of Africa and Asia. Because the condition is so widespread and serious, rotavirus vaccines should be included in all national immunization programmes and considered a priority, particularly in countries with high associated death rates, such as in south and south-eastern Asia and sub-Saharan Africa.

The addition of Rotasil to the WHO list of Prequalified vaccines will help to expand the global supply of rotavirus vaccines, increasing countries’ options to address the disease. It is also possible that it will reduce the price of available quality-assured vaccines through greater competition.

More info at http://www.who.int/medicines/news/2018/prequalified_new-rotavirus_vaccine/en/

 
 
IFPMA   [to 27 Oct 2018 ]
http://www.ifpma.org/resources/news-releases/
No new digest content identified.
 
 
PhRMA    [to 27 Oct 2018 ]
http://www.phrma.org/press-room
No new digest content identified.
 
 
Industry Watch
:: Johnson & Johnson Announces Promising, Early-Stage Results for Tetravalent Mosaic-based HIV Preventive Vaccine Regimen
– TRAVERSE data add to body of clinical evidence supporting further study of Janssen’s investigational mosaic-based vaccine regimen –
MADRID, SPAIN, 22 October 2018 – Johnson & Johnson today announced the primary analysis of immune response data for a tetravalent mosaic-based preventive vaccine against HIV-1 infection in development at the Janssen Pharmaceutical Companies of Johnson & Johnson. In the early-stage, Phase 1/2a TRAVERSE study among HIV-negative volunteers, a vaccine regimen including a tetravalent (4-valent) mosaic viral vector was compared to a regimen containing a trivalent (3-valent) mosaic vector. At 28 weeks, the tetravalent mosaic-based vaccine was well tolerated and significantly enhanced the breadth of immune responses to different HIV-1 strains compared to the trivalent version. These Phase 1/2a data will be shared this week at the 2018 HIV Research for Prevention Conference (HIVR4P) in Madrid, Spain. The tetravalent vaccine is now in large-scale efficacy testing.

“We urgently need new prevention tools to turn the tide of the HIV pandemic, and an effective preventive vaccine would be a vital asset to help us achieve an HIV-free future,” said Hanneke Schuitemaker, Ph.D., Vice President, Head Viral Vaccine Discovery and Translational Medicine, Janssen Vaccines & Prevention B.V. “Our goal is to develop a universal vaccine that could be deployed against any strain of HIV circulating in the world.”

Developing an effective vaccine against HIV has proven challenging due in part to the significant global genetic diversity of the virus. Janssen’s investigational vaccine regimen contains mosaic immunogens (molecules capable of inducing an immune response) that have been created using genes from a wide variety of HIV-1 subtypes. Both the trivalent and tetravalent versions of the mosaic-based vaccine contain viral vectors that deliver immunogens designed to elicit immune responses against the three main proteins of HIV (Env, Pol and Gag). But the tetravalent formulation adds a fourth immunogen, which is Env-focused and designed to enhance the breadth of immune responses against HIV-1 subtypes.

These new TRAVERSE results build on encouraging safety and immune response results for the mosaic-based vaccine from the Phase 1/2a APPROACH study that were shared at the 22nd International AIDS Conference (AIDS 2018). Early findings from TRAVERSE and APPROACH were critical in enabling the first large-scale efficacy study for a mosaic-based vaccine regimen, HVTN 705/HPX2008 (also known as ‘Imbokodo’), to commence in November 2017. This Phase 2b study is assessing a regimen based on the tetravalent vaccine that was first clinically evaluated in the TRAVERSE study. It aims to enroll 2,600 women aged 18-35 in five sub-Saharan African countries to determine whether the vaccine is safe and efficacious in reducing HIV-1 infection in this population.

Results from HVTN 705/HPX2008 are expected in 2021. Additional large-scale studies will be needed to support licensure of the mosaic-based vaccine regimen against HIV-1.

Reports/Research/Analysis/Commentary/Conferences/Meetings/Book Watch/Tenders

Reports/Research/Analysis/Commentary/Conferences/Meetings/Book Watch/Tenders

Vaccines and Global Health: The Week in Review has expanded its coverage of new reports, books, research and analysis published independent of the journal channel covered in Journal Watch below. Our interests span immunization and vaccines, as well as global public health, health governance, and associated themes. If you would like to suggest content to be included in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

 

No new digest content identified.

Journal Watch

Journal Watch

   Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

The 1918 Influenza Pandemic: Lessons Learned and Not—Introduction to the Special Section

American Journal of Public Health
November 2018  108(11)
http://ajph.aphapublications.org/toc/ajph/current

INFLUENZA PANDEMICS, 1918–2018
The 1918 Influenza Pandemic: Lessons Learned and Not—Introduction to the Special Section
Global Health, History, Immunization/Vaccines, Infections, Prevention, Other Infections, Community Health
Wendy E. Parmet and Mark A. Rothstein
108(11), pp. 1435–1436